Skip to main content
SpringerLink
Log in
Book cover

Cancer Chemotherapy by Infusion pp 35–40Cite as

The Clinical Pharmacology of Infusional Chemotherapy

  • Chapter

Abstract

Increasing interest in administering anticancer chemotherapy via prolonged systemic infusion is predicated on a number of observations. The first is that both acute and chronic normal tissue toxicities may be ameliorated when some agents are delivered as a continuous infusion. It has been reported that the cardiac toxicity of Adriamycin (ADR),1–4 the pulmonary toxicity of bleomycin (BLM),5–7 the nephrotoxicity and neurotoxicity of cisplatin (DDP),8,9 streptozotocin and gallium nitrate,10 and the bone marrow toxicity of 5-fluorouracil (5-FU)12–15 are significantly reduced when these drugs are infused over a period of 1 to 180 days rather than as a bolus I.V. injection. Presumably, normal tissue toxicities are related in some way to peak drug concentrations. Importantly, antitumor activity may be preserved through use of these regimens, suggesting improved therapeutic index. Indeed, in some instances, patients may respond to infusional therapy after failing to respond to the same agent administered conventionally.16

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Legha SS, Benjamin RS, MacKay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 133–139.

    Google Scholar 

  2. Weiss A J, Manthal RW. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with a particular reference to lack of cardiac toxicity. Cancer 1977; 46:2046–52.

    Article  Google Scholar 

  3. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading dose: clinically effective with reduced incidence of cardiac toxicity. Cancer Treat Rep 1980; 64:47–51.

    PubMed  CAS  Google Scholar 

  4. Garnick MB, Weiss GR, Steele GD, et al. Clinical evaluation of long-term, continuous-infusion doxorubicin. Cancer Treat Rep 1983; 67:133–42.

    PubMed  CAS  Google Scholar 

  5. Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978; 62:2011–17.

    PubMed  CAS  Google Scholar 

  6. Krakoff IH, Cuitkovic E, Currie V, Yeh S, LaMonte C. Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 1977; 40:2027–37.

    Article  PubMed  CAS  Google Scholar 

  7. Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 1981; 65:419–25.

    PubMed  CAS  Google Scholar 

  8. Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinum (II) by five-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 1984; 53:837–40.

    Article  PubMed  CAS  Google Scholar 

  9. Lokich JJ. Phase 1 study of cis-diamminedichloroplatinum(II) administered as a constant five-day infusion. Cancer Treat Rep 1980; 64:905–08.

    PubMed  CAS  Google Scholar 

  10. Seibert K, Golub G, Smiledge P, Nystram JN. Continuous streptozotocin infusion: a phase 1 study. Cancer Treat Rep 1979; 63:2035–37.

    PubMed  CAS  Google Scholar 

  11. Warvell RP, Coonley CJ, Straus DJ, Young CW. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 1983; 51:1982–87.

    Article  Google Scholar 

  12. Seifert P, Baker LH, Reed M, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36:123–28.

    Article  PubMed  CAS  Google Scholar 

  13. Hum CJ, Bateman JR. Five-day I.V. infusion with 5-fluorouracil for gastroenteric carcinoma after failure on weekly 5-FU therapy. Cancer Chemother Rep 1975; 59:1177–79.

    Google Scholar 

  14. Lokich J, Bothe A Jr, Fine N, Perri J. Phase 1 study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48:2565–68.

    Article  PubMed  CAS  Google Scholar 

  15. Lokich J, Fine N, Perri J, Bothe A Jr. Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol 1983; 6:103–08.

    PubMed  CAS  Google Scholar 

  16. Yap HY, Blumenschein GR, Keating MJ, et al. Vinblastine given as a continuous five-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 1980; 64:279–83.

    PubMed  CAS  Google Scholar 

  17. Shackney SE, Ritch PS. Cell kinetics. In: Chabner BA, ed. Pharmacologic principles of cancer treatment. Philadelphia: WB Saunders, 1982; 45–76.

    Google Scholar 

  18. Wan SH, Huffman DH, Azarnoff DL, et al. Effect of route of administration and effusion on methotrexate pharmacokinetics. Cancer Res 1974; 34:3487–91.

    PubMed  CAS  Google Scholar 

  19. Bleyer WA. The clinical pharmacology of methotrexate. Cancer 1978; 41:36–51.

    Article  PubMed  CAS  Google Scholar 

  20. Isacoff WH, Morrison PF, Aroesty J, et al. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1977; 61:1665–74.

    PubMed  CAS  Google Scholar 

  21. Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309:1094–1104.

    Article  PubMed  CAS  Google Scholar 

  22. Chan KK, Cohen JF, Gross JF, et al. Prediction of adriamycin disposition in cancer patients using a physiologic pharmacokinetic model. Cancer Treat Rep 1978; 62:1161–66.

    PubMed  CAS  Google Scholar 

  23. Reich SD. Clinical correlations of adriamycin pharmacology. Pharmacol Ther 1978; 2:239–45.

    CAS  Google Scholar 

  24. Bagley CM, Batich FW, DeVita VT. Clinical pharmacology of cyclophosphamide. Cancer Res 1973; 33:226–31.

    PubMed  Google Scholar 

  25. Juma FD, Rodgers HJ, Trounce JR. The pharmacokinetics of cyclophosphamide, phosphoramide mustard, and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 1980; 10:327.

    PubMed  CAS  Google Scholar 

  26. Nelson RL, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine and vinblastine in patients with cancer. Cancer Treat Rev 1980; 7:17–24.

    Article  PubMed  Google Scholar 

  27. Litterst CL, LeRoy AF, Guarino AM. The disposition and distribution of platinum following parenteral administration to animals of cis-dichlorodiammineplatinum (II). Cancer Treat Rep 1979; 63:1485–92.

    PubMed  CAS  Google Scholar 

  28. Patton TF, Himmelstein KJ, Belt R, et al. Plasma levels and urinary excretion of filterable platinum species following bolus injection and I.V. infusion of cis-dichlorodiammineplatinum-II in man. Cancer Treat Rep 1979; 63:1359–63.

    Google Scholar 

  29. Ho DH, Frei E. Clinical pharmacology of arabinofuranosylcytosine. Clin Pharmacol Therap 1971; 12:944–47.

    CAS  Google Scholar 

  30. Harris C. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukemia. Br J Clin Pharmacol 1979; 81:219–22.

    Google Scholar 

  31. Kirkwood JM, Ensminger W, Rosowsky A. Comparison of the pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a phase 1 clinical trial. Cancer Res 1980; 40:107–13.

    PubMed  CAS  Google Scholar 

  32. Curt GA, Clendeninn NJ, Chabner BA. Drug resistance in cancer. Cancer Treat Rep 1984; 68:87–99.

    PubMed  CAS  Google Scholar 

  33. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2:498–504.

    PubMed  CAS  Google Scholar 

  34. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol 1984; 2:1289–1304.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gregory A. Curt M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerry M. Collins Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Precept Press, Inc.

About this chapter

Cite this chapter

Curt, G.A., Collins, J.M. (1987). The Clinical Pharmacology of Infusional Chemotherapy. In: Cancer Chemotherapy by Infusion. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3193-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-3193-0_3

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7932-7

  • Online ISBN: 978-94-009-3193-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation